Is High LDL Cholesterol Actually Dangerous? The Evidence, The Myths, The Truth

Scientific concepts, discoveries, and nature/biological phenomena

LDL cholesterol as atherogenic particles

• LDL is carried in blood by lipoprotein particles that contain ApoB (apolipoprotein B).
• Each ApoB-containing particle carries one ApoB molecule, so ApoB concentration is interpreted as particle number.
• Core claim: atherosclerosis risk relates more to particle count (“particle burden”) than to cholesterol mass per particle.

LDL vs ApoB measurement and metabolic states

• LDL-C (standard lab LDL cholesterol) can be an imperfect proxy for particle number, especially when particle size changes (e.g., smaller/more numerous particles).
• ApoB is presented as a more direct marker of the number of atherogenic particles.

Causation framework for disease risk

The video outlines criteria to judge whether LDL/ApoB are causal for cardiovascular disease:

• Plausible biology/mechanism
• Association across populations
• Intervention reduces events (randomized trials)
• Genetic lifelong exposure reduces risk (Mendelian randomization)
• Dose-response scaling: greater lowering → greater risk reduction

Evidence supporting causality (the “three pillars”)

1. Randomized trials: LDL lowering reduces cardiovascular events

   • Statins: via the Cholesterol Treatment Trialists’ Collaboration meta-analysis.
   • PCSK9 inhibitors (examples mentioned):
     • FOURIER (evolocumab)
     • ODYSSEY OUTCOMES (alirocumab)
   • Cholesterol absorption inhibitor:
     • Ezetimibe (IMPROVE-IT trial) added to statins after acute coronary syndrome.
   • Claimed pattern: benefits occur across sexes, diabetics/non-diabetics, primary/secondary prevention, and scale with LDL reduction.

2. Mendelian randomization (“nature’s lifelong trial”)

   • Genetic variants that lower LDL/ApoB from birth are associated with lower lifetime cardiovascular risk.
   • Claimed effects track with ApoB/particle burden more than triglycerides or LDL-C alone.

3. Meta-regression across interventions

   • Across different drug classes, cardiovascular risk reduction is consistently proportional to the amount of LDL lowering.
   • Used to argue against drug-specific “off-target” effects.

Counterarguments and why they’re addressed

• Older adults: inverse association with all-cause mortality

  • Example source: Ravnskov et al. (BMJ, 2016) systematic review.
  • Limitations discussed:
    • All-cause mortality includes many non-atherosclerotic causes.
    • Reverse causation in frail/malnourished patients can lower LDL before death.
    • Mentions critiques by the Center for Evidence-Based Medicine (Oxford).

• “Half of heart attacks happen with normal LDL”

  • Framed as probabilistic risk: LDL is one factor among many (BP, smoking, diabetes, age, etc.).
  • Emphasizes lifetime exposure: LDL at the time of the event can look “normal” after years of prior exposure.

• Oxidized LDL / inflammation

  • The video accepts that oxidized LDL drives immune/inflammatory plaque processes (macrophages → foam cells).
  • Argument: you cannot oxidize LDL that isn’t present.
    • More ApoB particles → more arterial LDL substrate → more oxidation opportunity.
  • Therefore, lowering ApoB is framed as upstream prevention.

• LDL particle size (“small dense LDL is the real problem”)

  • Acknowledges small dense LDL can be more atherogenic in some contexts.
  • Claim: when ApoB is accounted for, added value of particle size shrinks or disappears.
  • Conclusion: particle number dominates over size.

• Coronary artery calcium (CAC) score

  • The video says CAC is useful for current calcified plaque (CT scan).
  • Limitations:
    • It’s a snapshot and misses non-calcified plaque.
    • Young people may have CAC = 0 despite ongoing plaque development.
  • Argues ApoB complements CAC and shouldn’t be ignored if ApoB is high.

• “LDL is a bystander/repair response” hypothesis

  • Discusses an idea (firefighters at fires analogy) that LDL accumulates at injury sites rather than causing them.
  • Rebuttal: genetics and randomized trials showing reduced outcomes with genetically/drug-lowered LDL are hard to reconcile with a purely bystander role.

Atherosclerosis begins early

• Pathobiological determinism from youth:
  • PDAY study (autopsies ages ~15–34) finds fatty streaks/early plaques correlate with risk factors like smoking, high BP, elevated cholesterol.
  • Bogalusa Heart Study similarly supports early lesion presence.
• Used to support cumulative lifetime exposure (“area under the curve” for ApoB burden).

Keto/low-carb discussion (“hyper-responders”)

• The video claims some individuals (“hyper-responders”) on ketogenic/very low-carb diets experience large ApoB/LDL increases (sometimes doubling/tripling).
• Mentions hypotheses/research:
  • Dave Feldman and the lean mass hyperresponder phenotype
  • Lipid energy model
  • Claim: in metabolically healthy, insulin-sensitive lean people, increased LDL might reflect altered lipid trafficking rather than harmful accumulation.
• Emphasizes: no long-term outcome data yet proving safety of very high ApoB in this group.
• Guidance implied: treat substantial ApoB rises as a red flag and consider diet changes and/or medication.

Big Pharma / funding bias (“big farmer” mentioned)

• Video acknowledges real conflicts of interest and potential industry influence on research.
• Argues LDL/ApoB causality is supported by multiple independent lines:
  • Benefits seen across different drug classes (not just statins)
  • Genetic evidence independent of drug companies
  • Meta-analyses using broad datasets
• Concludes a single conspiracy explanation is implausible given the breadth of evidence.

Longevity “blue zones” (nature/longevity phenomenon)

• Blue zones are defined as regions with unusually high survival past 90–100 and low chronic disease.
• Original blue zones mentioned:
  • Okinawa (Japan)
  • Sardinia (Italy)
  • Nicoya (Costa Rica)
  • Ikaria (Greece)
  • Loma Linda (California)
• Claim: dietary patterns generally align with lower saturated fat and favorable lipid profiles, consistent with lower ApoB/LDL particle exposure.
• Limitations:
  • Not controlled experiments
  • Confounders include genetics, activity, social ties, smoking, stress, healthcare access, and selection bias.

Residual cardiovascular risk

• Video argues residual risk after aggressive LDL lowering doesn’t disprove causality because:
  • Atherosclerosis is multifactorial (BP, diabetes, smoking, inflammation, endothelial dysfunction, genetics, etc.).
  • Reducing one driver lowers risk substantially but doesn’t eliminate risk to zero.

---

Methodologies / evidence approaches highlighted

• Randomized controlled trials (RCTs)

  • Randomize participants to LDL-lowering therapy vs placebo
  • Follow for years and count outcomes (heart attack, stroke, cardiovascular death/procedures)
  • Look for event reduction and scaling with amount of LDL lowering

• Meta-analysis / meta-regression

  • Combine results across many trials
  • Quantify the relationship between LDL reduction magnitude and event reduction

• Mendelian randomization (“genetic epidemiology”)

  • Identify inherited variants that lower LDL/ApoB lifelong
  • Compare cardiovascular outcomes vs non-carriers
  • Mimics lifelong intervention and reduces confounding from lifestyle/adherence

• Observational cohort critique framework

  • Evaluate whether associations are confounded by:
    • Competing causes of death (all-cause vs cardiovascular)
    • Reverse causation (illness leading to low LDL)

• Pathology/autopsy studies

  • Examine arterial lesions in youth (fatty streaks/early plaques)
  • Correlate lesion burden with traditional risk factors

• Imaging-based risk stratification

  • Coronary artery calcium (CAC/CACS) using CT to measure calcified plaque burden
  • Interpreted as a snapshot of existing calcification, not future risk alone

---

Researchers or sources featured (as named in the subtitles)

• Dr. Alex (speaker; emergency medicine doctor in the UK)
• Ravnskov (and colleagues; BMJ systematic review, 2016)
• Center for Evidence-Based Medicine (Oxford) (post-publication response critiquing methodology)
• Cholesterol Treatment Trialists’ Collaboration (CTTC) (meta-analysis of statin trials)
• FOURIER trial investigators (evolocumab)
• ODYSSEY OUTCOMES trial investigators (alirocumab)
• IMPROVE-IT trial investigators (ezetimibe added to statin)
• Dave Feldman (referenced in keto/lean hyper-responder discussion)
• PDAY investigators (Pathobiological Determinants of Atherosclerosis in Youth)
• Bogalusa Heart Study investigators
• Blue zone researchers (regions named; no individual investigator names were provided in the subtitles)